ICER offers policy recommendations in final report for cystic fibrosis drugs

ICER released its final evidence report June 7 on CF transmembrane conductance regulator (CFTR) therapies that found that while Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor and Symdeko tezacaftor/ivacaftor offered a net benefit compared with supportive care alone,

Read the full 359 word article

User Sign In